Norcliffe Capital are proud to support ClinSpec Diagnostics Ltd and the future of cancer diagnostics.
ClinSpec Dx, a Glasgow based spin out from the University of Strathclyde, have developed a cancer diagnostics system using a simple blood test analysis to accelerate the time it takes to diagnose cancer.
Based on the world-leading research of Dr Matthew Baker, tests have been carried out on brain, prostate and pancreatic cancers highlighting the technology’s potential as a multi-cancer early detection test.
Dr Mark Hegarty, CEO, ClinSpec Dx said:
“Achieving the £3.5m target enables us to accelerate our plans. We will shortly complete our move into new lab and office facilities and increase staffing to 15, bringing forward key operational and commercial appointments.
“Our two clinical studies on detection of brain cancer have been successful and papers are in draft for publication over the next 6 months. This, plus the development of our multi-cancer platform covering the most common cancers, will form the bedrock for Series A investment in 2022, with the target of commercial launch in 2024.
“We are also delighted to have further strengthened our leadership team by the appointment of Professor David Onions of Norcliffe Capital to the Board of Directors.”
ClinSpec Dx have raised £5.1M to date in association with Norcliffe Capital, Mercia Asset Management, Scottish Enterprise, Social Investment Scotland Ventures, EOS Advisory and the University of Strathclyde, as well as grant funding from the Higgs EDGE Special Award, and from Innovate UK through the precision medicine accelerator fund.
